ad image

Strategic Partnership

1 / 6
Cellex Cell Professionals
Announcement

Swarm Oncology and Cellex Cell Professionals Announce Partnership to Advance Swarm's T Cell Therapies for Solid Cancers

Cellex Cell Professionals

PR-02-25-NI-23Feb 24, 2025
Inceptor Bio
Announcement

Inceptor Bio and GRIT Bio Cooperate to Advance IB-T101, a Next-Generation Solid Tumor CAR-T Utilizing the OUTLAST™ Platform

Inceptor Bio

PR-12-24-NI-142Dec 18, 2024
How are Advancements in Technology Reshaping the Roles and Capabilities of CDMOs and CROs in the Drug Development Life Cycle?
Changing Roles

How are Advancements in Technology Reshaping the Roles and Capabilities of CDMOs and CROs in the Drug Development Life Cycle?

Pharma's Almanac

PAO-08-24-RT-01Aug 07, 2024
Rethinking the Conventional CDMO Model
CDMO Model

Rethinking the Conventional CDMO Model

Wheeler Bio

PAO-08-24-CL-04Jul 29, 2024
Building a Path to Approval with Effective Regulatory Support
Regulatory

Building a Path to Approval with Effective Regulatory Support

Mira Han

Samsung Biologics

PAO-07-24-CL-12Jul 29, 2024
Why Fina Biosolutions Partnered With Scorpius BioManufacturing for cGMP Production of EcoCRM® (CRM197)
CDMO Selection

Why Fina Biosolutions Partnered With Scorpius BioManufacturing for cGMP Production of EcoCRM® (CRM197)

Scorpius BioManufacturing

PAO-11-23-CL-04Dec 08, 2023
Samsung Biologics
Strategic Partnership

Samsung Biologics and Kurma Partners Announce Strategic Partnership for Development and Manufacturing of Biologics for Kurma’s Portfolio Companies

Samsung Biologics

PR-M10-23-06Oct 24, 2023
Webinar: A Developer's Guide to Partnering With the Right CDMO, Presented by Samsung Biologics
CDMO Partnerships

Webinar: A Developer's Guide to Partnering With the Right CDMO, Presented by Samsung Biologics

Samsung Biologics

PAO-08-23-PATV-01Aug 16, 2023
Why Choosing the Right CDMO Partner is Essential in Today’s Pharmaceutical Market
CDMO Partnerships

Why Choosing the Right CDMO Partner is Essential in Today’s Pharmaceutical Market

Daniel Buckley

Samsung Biologics

PAO-05-23-CL-07Jun 19, 2023
Hovione
Strategic Partnership

Hovione and Laxxon Medical Establish an Agreement for the cGMP Production of 3D Screen Printed Pharmaceutical Applications

Hovione

PR-M03-23-06Mar 22, 2023
Improving the Therapeutic Index of ADCs with a Peptide Linker Technology
ADCS

Improving the Therapeutic Index of ADCs with a Peptide Linker Technology

Philipp Spycher

Araris Biotech AG

PAO-07-022-CL-01Jul 07, 2022
Advanced Instruments
Cell Line Development

Wheeler Bio Integrates the Solentim® Ecosystem by Advanced Instruments to Deliver the Highest Level of Consistency Across Their Cell Line Development Workflow

Advanced Instruments

PR-M06-22-04Jun 14, 2022
Tuning the Myeloid Compartment with a Best-in-Class CDMO
Immuno-Oncology

Tuning the Myeloid Compartment with a Best-in-Class CDMO

Kiren Khanduga; Alicia Levey, Ph.D.

Pionyr Immunotherapeutics

PAO-06-022-CL-04Jun 06, 2022
Reducing Time to IND, Increasing Quality, and Building Trust through Shared Data
Digitalization

Reducing Time to IND, Increasing Quality, and Building Trust through Shared Data

David Alvaro, Ph.D.; Christa Short; Jesse McCool, Ph.D.; Lance Johnson; Markus Gershater, Ph.D.; Michael Sokolov, Ph.D.; Yuk Chun Chiu, M.S.E.; Guy Levy-Yurista, Ph.D.; David Schmidt, M.B.A., M.Sc.

Pharma's Almanac

PAO-05-022-CL-01May 18, 2022
Strategic Partnerships for Pharma's Chemistry Needs
Chemistry

Strategic Partnerships for Pharma's Chemistry Needs

Therachem Laboratories

PAO-05-22-R250-04May 12, 2022
DFE Pharma
Strategic Partnership

DFE Pharma, Harro Höfliger, and Sterling Partner in “INTO” to Provide Formulation Services for Respiratory Products

DFE Pharma

PR-M03-22-16Mar 29, 2022
Chimeric Therapeutics
Strategic Partnership

Chimeric Partners With Be The Match BioTherapies® To Advance CHM 1101 (CLTX CAR T)

Chimeric Therapeutics

PR-M03-22-07Mar 17, 2022
Hovione
Strategic Partnership

Hovione and Zerion Pharma Announce a Strategic Partnership to Market the Dispersome® Technology Platform

Hovione

PR-M02-22-19Feb 22, 2022
eTheRNA Immunotherapies NV
Strategic Partnership

eTheRNA Announces Research Agreement with Merck KGaA, Darmstadt, Germany to Access mRNA Technologies

eTheRNA Immunotherapies NV

PR-M02-22-02Feb 03, 2022
Serving an Accelerated Market with mRNA Production
mRNA Manufacturing

Serving an Accelerated Market with mRNA Production

Mark Bamforth

Arranta Bio

PAO-11-21-CL-06Dec 08, 2021
1 / 6